Split History
ETFs Holding ACRX »    ACRX Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Co.'s portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Co.'s sufentanil sublingual products and product candidates include DSUVIA®, which is indicated for use in adults in supervised healthcare settings; Zalviso®, which is intended for the management of moderate-to-severe acute pain in hospitalized adult patients; and ARX-02, which is for cancer breakthrough pain in opioid-tolerant patients. According to our ACRX split history records, AcelRx Pharmaceuticals has had 1 split.
ACRX split history picture
AcelRx Pharmaceuticals (ACRX) has 1 split in our ACRX split history database. The split for ACRX took place on October 26, 2022. This was a 1 for 20 reverse split, meaning for each 20 shares of ACRX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.

When a company such as AcelRx Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the ACRX split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AcelRx Pharmaceuticals shares, starting with a $10,000 purchase of ACRX, presented on a split-history-adjusted basis factoring in the complete ACRX split history. ACRX split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/02/2013
End date: 03/28/2023
Start price/share: $98.80
End price/share: $0.69
Dividends collected/share: $0.00
Total return: -99.30%
Average Annual Total Return: -39.15%
Starting investment: $10,000.00
Ending investment: $69.88
Years: 9.99
Date Ratio
10/26/20221 for 20
ACRX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ACST Split History
ACUR Split History
ADK Split History
ADMP Split History
ADMS Split History
ADPT Split History
ADRO Split History
ADXS Split History
AEMD Split History
AEZS Split History

Also explore: ACRX shares outstanding history

Email EnvelopeFree ACRX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Allarity Therapeutics, Inc. (ALLR)
BK Technologies Corporation (BKTI)
Cuentas, Inc. (CUEN)
Protagenic Therapeutics, Inc. (PTIX)
Luokung Technology Corp. (LKCO)
NioCorp Developments Ltd. (NB.CA)
Mexican Gold Mining Corp. (MEX.CA)
New York Mortgage Trust, Inc. (NYMT)
Kaleyra, Inc. (KLR)
Harbor Custom Development, Inc. (HCDI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ACRX Insider Buying

ACRX Split History | www.SplitHistory.com | Copyright © 2013 - 2023, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.